Scion NeuroStim Raises $10 Million in Equity Funding

Why It Matters:

This funding announcement is significant as it showcases investor confidence in Scion NeuroStim's mission to develop innovative and non-invasive neuromodulation medical devices for patients with central nervous system diseases and disorders.

The Details:

• Scion NeuroStim has filed with the SEC to disclose $9,999,978 in equity funding from 13 investors.

• The company is dedicated to improving the lives of patients through the development of easy-to-use medical devices.

• The website highlights 21 patents and mentions pending patents in the U.S. and internationally.

• The FDA has not granted marketing authorization for Scion NeuroStim's products, and they are currently unavailable for sale.

• Scion NeuroStim was initially formed in 2007 and converted to a business corporation in January of last year.

• Lanty Smith and Steven Bischoff are listed as directors in both the company and SEC filing.

• Lesco Rogers, identified as a "director" in the SEC filing, serves as the company's Chief Medical Officer according to LinkedIn.

• Rober Black, the company's CTO and COO, signed the SEC filing.

Conclusion:

Scion NeuroStim's recent $10 million equity funding provides a boost to its mission of developing innovative medical devices for patients with central nervous system diseases and disorders. With a focus on non-invasive neuromodulation, the company aims to make a difference in patient care.